Compare WOOF & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOOF | OBX |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.2M | 848.8M |
| IPO Year | 2020 | 2026 |
| Metric | WOOF | OBX |
|---|---|---|
| Price | $2.45 | $12.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $3.47 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 3.6M | 541.6K |
| Earning Date | 12-08-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.11 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $5,961,467,000.00 | N/A |
| Revenue This Year | $0.46 | N/A |
| Revenue Next Year | $1.23 | N/A |
| P/E Ratio | $30.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.14 | $9.60 |
| 52 Week High | $3.78 | $39.00 |
| Indicator | WOOF | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 42.10 |
| Support Level | $2.21 | $11.84 |
| Resistance Level | $2.51 | $15.87 |
| Average True Range (ATR) | 0.17 | 1.60 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 2.76 | 43.34 |
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.